Anixa Biosciences, Inc. (ANIX)
NASDAQ: ANIX · Real-Time Price · USD
2.880
-0.040 (-1.37%)
At close: Feb 20, 2026, 4:00 PM EST
3.080
+0.200 (6.94%)
After-hours: Feb 20, 2026, 7:52 PM EST

Anixa Biosciences Income Statement

Millions USD. Fiscal year is Nov - Oct.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Oct '25 Oct '24 Oct '23 Oct '22 Oct '21
--0.21-0.51
Cost of Revenue
--0.16-0.39
Gross Profit
--0.05-0.13
Selling, General & Admin
6.637.446.297.177.07
Research & Development
5.076.44.776.76.19
Operating Expenses
11.713.8311.0613.8813.26
Operating Income
-11.7-13.83-11.01-13.88-13.14
Interest & Investment Income
0.671.131.080.10
EBT Excluding Unusual Items
-11.03-12.7-9.93-13.77-13.13
Gain (Loss) on Sale of Assets
----0.01
Pretax Income
-11.03-12.7-9.93-13.77-13.13
Earnings From Continuing Operations
-11.03-12.7-9.93-13.77-13.13
Minority Interest in Earnings
0.10.140.120.180.17
Net Income
-10.93-12.55-9.81-13.6-12.95
Net Income to Common
-10.93-12.55-9.81-13.6-12.95
Shares Outstanding (Basic)
3232313029
Shares Outstanding (Diluted)
3232313029
Shares Change (YoY)
1.74%2.96%1.99%6.28%28.57%
EPS (Basic)
-0.34-0.39-0.32-0.45-0.45
EPS (Diluted)
-0.34-0.39-0.32-0.45-0.45
Free Cash Flow
-7.17-7.34-6.21-6.49-4.94
Free Cash Flow Per Share
-0.22-0.23-0.20-0.21-0.17
Gross Margin
--23.33%-24.80%
Operating Margin
---5243.33%--2565.63%
Profit Margin
---4671.91%--2530.08%
Free Cash Flow Margin
---2956.67%--964.45%
EBITDA
-----13.1
D&A For EBITDA
----0.04
EBIT
-11.7-13.83-11.01-13.88-13.14
Updated Oct 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q